Category Archives: Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells Market to Grow with an Impressive CAGR – Farming Sector

The global market for induced pluripotent stem cells (iPSCs) reached $2.1 billion in 2016. The market should reach $3.6 billion in 2021, increasing at a compound annual growth rate (CAGR) of 11.6% from 2016 through 2021.

Report Scope:

This study is focused on the market side of iPSCs rather than its technical side. Different market segments for this emerging market are covered. For example, application-based market segments include academic research, drug development and toxicity testing, and regenerative medicine; product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation and cell analysis; iPSC-derived cell-type-based market segments include cardiomyocytes, hepatocytes, neurons, endothelia cells and other cell types; geography-based market segments include the U.S., Europe, Asia-Pacific and Rest of World. Research and market trends are also analyzed by studying the funding, patent publications and research publications in the field.

Get PDF Sample for the Report:https://www.trendsmarketresearch.com/report/sample/12035

Report Includes:

An overview of the global market for induced pluripotent stem cells. Analyses of global market trends with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021. Information on induced pluripotent stem cell research products, defined as all research tools including but not limited to: induced pluripotent stem cells and various differentiated cells derived from induced pluripotent stem cells; various related assays and kits, culture media and medium components, such as serum, growth factors and inhibitors, antibodies, enzymes, and many others that can be applied for the specific purpose of executing induced pluripotent stem cell research. Discussion of important manufacturers, technologies, and factors influencing market demand, such as the driving forces and limiting factors of induced pluripotent stem cell market growth. Profiles of major players in the industry.

Report Summary

Its been over 10 years since the discovery of induced pluripotent stem cell (iPSC) technology. The market has gradually become an important part of the life sciences industry during recent years. Particularly for the past five years, the global market for iPSCs has experienced a rapid growth. The market was estimated at $1.7 billion in 2015 and over $2 billion in 2016, with an average 18% growth. The overall iPSC market is forecast to continue its relatively rapid growth and reach over $3.6 billion in 2021, with an estimated compound annual growth rate (CAGR) of 11.6% from 2016 through 2021.

You can Buy This Report from Here @https://www.trendsmarketresearch.com/checkout/12037/Single

Key Drivers for Market Growth

This report has identified several key drivers for the rapidly growing market: iPSC shold promising hope for therapeutic solutions for diseases without ethical issues. A series of technical breakthroughs were made in recent years for improving cellular reprogramming, differentiation and large-scale production of GMP- grade iPSCs derived cells toward clinical usability. The pharmaceutical industry needs better cell sources such as iPSC-derived functional cells for drug toxicity testing and drug screening. The U.S. government has been encouraging the marketing of stem cells, including iPSCs. The U.S. Food and Drug Administration (FDA) has been authorized to provide orphan drug designations for many of the therapies developed for rare diseases such as Parkinsons and Huntingtons using stem cells. The provisions of grants from organizations, such as the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) have been encouraging for the research institutes to venture into iPSC research. Rapidly growing medical tourism and contract research outsourcing drives the Asia-Pacific stem cell market. Cellular reprogramming, including iPSC technology, was awarded the 2012 Nobel Prize. The first human iPSC clinical trial started in August 2014, and the recent report of the first macular degeneration patient treated with the sheets of retinal pigmented epithelial cells made from iPSCs was encouraging. iPSC technology is developing into a platform for precision and personalized medicine, which is experiencing rapid growth globally. New biotechnologies such as genome editing technology are advancing iPSCs into more and better uses.

This report identifies key revenue segments for the iPSC market from various aspects. The applicationbased segments include the research, drug development and clinical markets; the product functionbased segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation and cell analysis. The current major revenue segment is the drug development and toxicity testing sector, but the market for regenerative medicine is the fastest growing one. The market for clinical applications is not fully established, but the market for the translational medicine research of iPSC is also growing very quickly.

Read the original here:
Induced Pluripotent Stem Cells Market to Grow with an Impressive CAGR - Farming Sector

Accelerating cell-based therapies by providing safe therapeutic MSC products – BioSpace

TORONTO, Jan. 8, 2021 /CNW/ -panCELLa's intent to develop therapeutic products in the mesenchymal stem cell (MSC) and pancreatic islet space has recently led to the creation of Implant Therapeutics.

Implant Therapeutics, under the guidance of Dr. Mahendra Rao, is engineering iPSC-MSC cells containing panCELLa's FailSafe and induced Allogeneic Cell Tolerance (iACT Stealth Cell) technologies. These iPSC MSC cells are hypo-immunogenic and are an ideal choice for bone, cartilage and tendon replacement strategies combining the advantages of allogeneic and autologous cells as well as allowing them to be used as ex-vivo gene therapy vehicles.

Implant is pleased to announce a definitive cross licensing agreement with RxCell. The collaboration will allow both companies to rapidly move forward in their respective fields with enhanced technology platforms, access to cGMP grade iPSC lines and the ability to generate a wide variety of therapeutic grade products.

"RxCell's hypo-immunogenic cell platform complements our cloaking platform and allows us to develop novel tissue-specific hypo-immunogenic cell lines" said Dr. Andras Nagy, the inventor of the cloaking technology otherwise known as panCELLa's iACT (Stealth Cells). Dr. Zeng added that she was particularly pleased to have access to cGMP grade engineered Master Cell Banks that utilized Sigma/Merck CRISPR-based technology to incorporate the safe harbor technology.

Dr. Rao CEO of Implant Therapeutics added "I believe that the MSC platform developed by the two companies combines the proven power of MSC with the engineering expertise of panCELLa and this will make RxCell and Implant leaders in their respective fields."

About Implant Therapeutics

Implant provides hypoimmunogenic and safe harbor engineered IPSC derived cellsin order to deliver the ultimate therapeutic MSC products. To learn more, visit https://www.implant-rx.com/

About panCELLa

Founded in 2015, panCELLa is a privately-held early-stage biotechnology firm based on the innovative technology developed in Dr. Andras Nagy's lab at the Sinai Health System (SHS). panCELLa has created platforms that allow for the development of safe, universal, "off-the-shelf" cell lines. To learn more, visit https://pancella.com.

About RxCell

RxCell is a biotechnology company focused on therapeutic applications of induced pluripotent stem cells (iPSC). We have developed several therapeutic grade iPSC line seed banks and are in the process of manufacturing a large Master Cell Bank to support our activities. To learn more, visit https://www.rxcellinc.com/

SOURCE panCELLa Inc.

Read this article:
Accelerating cell-based therapies by providing safe therapeutic MSC products - BioSpace

Exacis Biotherapeutics Announces Its Launch and mRNA Technology In-Licensing For Targeted CAR-NK And CAR-T Cell Cancer Therapies | DNA RNA and Cells |…

Details Category: DNA RNA and Cells Published on Friday, 08 January 2021 07:36 Hits: 379

-- Focuses on immuno-oncology

-- Creates innovative, engineered T and NK cells from induced pluripotent stem cells (iPSC)

-- In-licenses mRNA technologies developed by Factor Bioscience

-- Uses mRNA-based approach to create cell therapies - avoids viruses and DNA

-- Names key executives including Gregory Fiore, MD, as Chief Executive Officer

CAMBRIDGE, MA, USA I January 6, 2021 I Exacis Biotherapeutics, Inc., a development-stageimmuno-oncology company working to harness the immune system to cure cancer,today announcedits formation along with completion of in-licensing of certain technologies from Factor Bioscience, a leading cell sciences company. The exclusive license allows Exacis to create allogeneic engineered T and NK cells from induced pluripotent stem cells (iPSC). Exacis'next generation approachavoids useof DNA andviruses by usingmRNA.The technologies will be used for generatingiPSC and for performing genetic editing to create stealthed, allogeneic cell products, termed ExaCAR-Tor ExaCAR-NKcells.

Exacis also announcedthe addition of key members to its leadership team, Scientific Advisory Board and Board of Directors. Gregory Fiore, MD,a Harvard trained physician, seasoned pharmaceutical executiveand serial entrepreneur, has been named Chief Executive Officer.Dr. Fiore is joined on the management team by co-founder and Head of Discovery and Development, James Pan, PhD,an entrepreneur andbiologics expert. DimitriosGoundis, PhD, formerly CEO of MaxiVAX, a private Swiss immuno-oncology company, joins Exacis as the Chief Business Officer.

Exacis was launched by Factor Bioscience with an exclusive license to its intellectual property for developing targeted, allogeneic cell therapies for cancer treatment. Factor CEO Matthew Angel, PhD,is the Chair of Exacis'Scientific Advisory Board and is joined on the SAB by Factor Co-Founder Christopher Rohde, PhD, Eric Westin, MD,and Gunnar Kaufmann, PhD. Exacis' Board of Directors is chaired by Mark Corrigan,MD, a highly successfuldrug developer,biotechnology CEO and Board Chairperson.

Commenting on the new endeavor, Dr. Fiore said, "This is a wonderful opportunity to create innovative, next-generation NK and T cell therapies to improve outcomes and experiences for patients with challenging liquid and solid tumors."

Exacis' Board Chairman Corrigan added, "The ground- breaking science Exacis has in-licensed, along with the team we are building, provide a strong foundation for developing successful targeted cell therapies for the treatment of cancer."

Exacis has secured initial seed funding and is seeking to raise Series A funding in early 2021. The company has initiated discussions with several potential development collaborators.

About Exacis Biotherapeutics

Exacis is a development stage biotechnology company focused on harnessing the human immune system to cure cancerby engineering off-the-shelf NK and T cell therapies aimed at liquid and solid tumors.Exacis was founded in 2020 with an exclusive license to a broad suite of patents covering the use oftechnologies developed by Factor Biosciences.

About Factor Bioscience

Founded in 2011, Factor Bioscience develops technologies for engineering cells to advance the study and treatment of disease. It actively licenses its technologies to entities wishing to conduct commercial research, sell tools, reagents and other products, perform commercial services for third parties, and develop human and veterinary therapeutics. Factor Bioscience is privately held and is headquartered in Cambridge, MA.

About T and Natural Killer (NK) Cell Therapies

T and NK cells are types of human immune cells that are ableto recognize and destroy cancer cells and can be modified through genetic engineering to target specific tumors.

SOURCE: Exacis Biotherapeutics

See the original post here:
Exacis Biotherapeutics Announces Its Launch and mRNA Technology In-Licensing For Targeted CAR-NK And CAR-T Cell Cancer Therapies | DNA RNA and Cells |...

Environmental Factor – January 2021: Intramural Papers of the Month – Environmental Factor Newsletter

Intramural Papers

Intramural By Sanya Mehta, Victoria Placentra, Saniya Rattan, Nancy Urbano, Qing Xu

Researchers in the Division of the National Toxicology Program (DNTP) examined the long-term use of hydroxyurea (HU) therapy, the most effective strategy for managing sickle cell anemia, a genetic disorder of the blood. HU effectively increases healthy fetal hemoglobin production, but through a mechanism that is harmful to cells. The use of HU and its adverse side-effects are well-managed in adults. However, the U.S. Food and Drug Administration only recently approved HU for use in children and data is limited for understanding the impact the drug may have on child development.

The scientists conducted critical preliminary studies to identify appropriate doses for evaluating long-term effects. They assessed HU kinetics, or the movement of the chemical in the body, during critical periods of rodent development. HU was administered to pregnant rats from late gestation through lactation and to their offspring for 34 days after birth. Decreased body weight and adverse clinical observations, such as hair loss, appeared in offspring receiving at least 75 milligrams per kilogram per day. Data revealed gestational transfer of HU, but minimal lactational transfer. There was no difference in the half-life of HU between age and sex, but systemic exposure decreased with increasing age. (SM)

Citation:Huang MC, Turner KJ, Vallant M, Robinson VG, Lu Y, Price CJ, Fennell TR, Silinski MA, Waidyanatha S, Ryan KR, Black SR, Fernando RA, McIntyre BS. 2020. Tolerability and age-dependent toxicokinetics following perinatal hydroxyurea treatment in Sprague Dawley rats. J Appl Toxicol; doi:10.1002/jat.4087 [Online 25 November 2020].

Individual heterogeneity, or genetic variability, can substantially affect reprogramming of somatic cells into induced pluripotent stem cells (iPSCs), according to NIEHS scientists and their collaborators. iPSCs are stem cells that are derived from differentiated cells, such as fibroblasts, and they can both self-renew and are pluripotent, meaning they can be differentiated into other cell-types. In a previous publication, the research team obtained fibroblasts tissue cells from healthy, diverse donors and observed that each persons fibroblasts had consistent differences in the ability to be reprogrammed to iPSCs. Ancestry was identified as a large contributing factor. In this publication, the research team identified genes and pathways that may be responsible for the observed differences.

Using 72 dermal fibroblast-iPSCs from self-identified African Americans and white Americans, the researchers found ancestry-dependent and ancestry-independent genes associated with reprogramming efficiency. These include genes involved in intracellular transport regulation, protein localization, and cytoskeletal organization, as well as dynamic biological processes like cancer and wound healing. The findings suggest that the heterogeneity of an individual can influence iPSC reprogramming, and the scientists suggested that these genes will provide insights into ancestry-dependent regulation of cell fate and reprogramming. (NU)

Citation:Bisogno LS, Yang J, Bennett BD, Ward JM, Mackey LC, Annab LA, Bushel PR, Singhal S, Schurman SH, Byun JS, Napoles AM, Perez-Stable EJ, Fargo DC, Gardner K, Archer TK. 2020. Ancestry-dependent gene expression correlates with reprogramming to pluripotency and multiple dynamic biological processes. Sci Adv 6(47):eabc3851.

NIEHS researchers and their collaborators have developed tools to deliver diphosphoinositol polyphosphates (PP-InsPs) into cultured cells to study their actions. The PP-InsPs are multipurpose cell signaling molecules that regulate diverse biological processes. The few tools that exist to study PP-InsP activities in living cells require hours-long procedures and are plagued by the possibility of off-target effects, thereby compromising short-term studies.

Because the PP-InsPs are highly charged, they cannot enter cells. Therefore, the researchers masked the charge by encapsulating the PP-InsPs inside liposomes. These are minute spherical sacs of phospholipid molecules are similar to those found in cell membranes, except that the researchers used phospholipids that melt at 40 degrees Celsius (i.e., fractionally above body temperature). The liposomes also contain a dye that warms when exposed to biologically harmless red light. These liposomes are readily accumulated by the cells. Finally, the cells are briefly placed under red light for two to five minutes, causing the liposomes to heat, melt, and release their PP-InsP cargo.

To validate this new delivery method, the scientists developed a fluorescent PP-InsP analogue and monitored its release into cells. This new intracellular PP-InsP delivery method is adjustable and applicable to all PP-InsPs and analogs. (SR)

Citation:Wang Z, Jork N, Bittner T, Wang H, Jessen HJ, Shears SB. 2020. Rapid stimulation of cellular Pi uptake by the inositol pyrophosphate InsP8 induced by its photothermal release from lipid nanocarriers using a near infra-red light-emitting diode. Chem Sci 11:1026510278.

In a study of pregnant women in Bangladesh, taking vitamin D supplements was associated with nonsignificant increases in lead levels, but significant increases in cord blood levels of lead and cadmium, according to NIEHS researchers and their collaborators. Vitamin D is important for building healthy bones, but animal studies indicate it increases the absorption of toxic metals a body is exposed to, such as lead, cadmium, manganese, and mercury. The study was the first to examine the effect of prenatal vitamin D supplementation and blood metal levels in a randomized clinical trial.

In the study, 1,300 pregnant women were randomized into groups that received a placebo or weekly doses of either 4,200, 16,800, or 28,000 international units (IU) of vitamin D3.

Randomization occurred in the second trimester and supplementation or placebo were continued throughout pregnancy. At delivery, maternal blood and umbilical cord blood samples were collected, and researchers measured their cadmium, lead, mercury, and manganese levels using a technique called inductively coupled plasma mass spectrometry. The pregnant women who received vitamin D supplementation showed no significant increase in blood metal concentrations compared to the placebo group. However, they were more likely to have infants with higher cord blood lead levels and with detectable cadmium. The authors say further investigation is needed since there is no safe level of toxic metals for infants. (VP)

Citation:Jukic AMZ, Zuchniak A, Qamar H, Ahmed T, Mahmud AA, Roth DE. 2020. Vitamin D treatment during pregnancy and maternal and neonatal cord blood metal concentrations at delivery: Results of a randomized controlled trial in Bangladesh. Environ Health Perspect 128(11):117007.

NIEHS researchers and their collaborators have revealed that genetic factors contribute to development of hypothalamic amenorrhea (HA), a condition in which menstruation stops in women of reproductive age. The finding provides new insight into the development of HA and womens reproductive health.

Studies have shown that HA is more prevalent in women with excessive exercise, food restriction, or psychological stress. Both physical and emotional stressors could cause altered secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus in the brain. GnRH deficiency, in turn, impairs the synthesis of gonadotropins that are essential for reproduction and fertility and leads to hypogonadotropic hypogonadism (HH). Several rare, pathogenic sequence variants in genes that control the development or function of GnRH have been identified in individuals with a rare syndrome called isolated hypogonadotropic hypogonadism (IHH), an inherited form of HH. Due to the varied menstrual and hormonal response to similar stressors, this study investigated whether genetic variation influenced individual susceptibility to known risk factors for HA.

The researchers sequenced all the protein-coding regions of genes in women with HA and women in the control group. After comparing the frequency of rare variants in more than 50 IHH-associated genes, they found HA patients had a greater burden of variants than the control heathy women, confirming the genetic impact on the development of HA. (QX)

Citation:Delaney A, Burkholder AB, Lavender CA, Plummer L, Mericq V, Merino PM, Quinton R, Lewis KL, Meader BN, Albano A, Shaw ND, Welt CK, Martin KA, Seminara SB, Biesecker LG, Bailey-Wilson JE, Hall JE. 2020. Increased burden of rare sequence variants in GnRH-associated genes in women with hypothalamic amenorrhea. J Clin Endocrinol Metab; doi: 10.1210/clinem/dgaa609 [Online 1 September 2020].

(Sanya Mehta is an Intramural Research Training Award [IRTA] postbaccalaureate fellow in the NIEHS Matrix Biology Group. Victoria Placentra is an IRTA postbaccalaureate fellow in the NIEHS Mutagenesis and DNA Repair Regulation Group. Saniya Rattan, Ph.D., is an IRTA fellow in the NIEHS Reproductive Developmental Biology Group. Nancy Urbano is an IRTA postbaccalaureate fellow in the DNTP Predictive Toxicology and Screening Group. Qing Xu is a biologist in the NIEHS Metabolism, Genes, and Environment Group.)

See the original post here:
Environmental Factor - January 2021: Intramural Papers of the Month - Environmental Factor Newsletter

Global Induced Pluripotent Stem Cells Market To Witness Huge Gains Over 2020-2026 – Factory Gate

The globalInduced Pluripotent Stem Cells marketresearch report is based on the market and extends over all particulars of the market factors. The report further contains detailed specification about the Induced Pluripotent Stem Cells market size in terms of sales, revenue and value. The report contains the detailed segmentation {Adult Sources, Fetal Sources, Others}; {Hematopoietic stem cell transplantation, Tissue repair damage, Autoimmune diseases, As gene therapy vectors.} of the Induced Pluripotent Stem Cells market, gives us the information of the global market and makes the forecasting about the market status in the coming future.

Our Research Analyst implemented a Free PDF Sample Report copy as per your Research Requirement, also including impact analysisofCOVID-19 onInduced Pluripotent Stem Cells Market Size

Get Free Sample of this Induced Pluripotent Stem Cells Report Here:https://www.marketresearchstore.com/report/global-induced-pluripotent-stem-cells-market-report-2018-269066#RequestSample

In order to analyze the data and to understand the competition of the Induced Pluripotent Stem Cells market, the use of the Porters five forces model is made during the research. The report consists of detail segmentation of the market, factors contributing to the growth and restraining factors of the Induced Pluripotent Stem Cells market.

Induced Pluripotent Stem Cells Market COVID-19 Impact Analysis

The outbreak of COVID-19 was sudden and was not at all considered so dangerous when it first struck at Wuhan city of China. Although, everything in that city was closed but the coronavirus infection had wide spread in China as a wild fire. Within months it spread to the neighboring countries and then to every single country in the world. The World Health Organization announced it as a pandemic and till then it had created huge losses in several countries.

The listing supplies hints on the Upcoming pointers:

1.Business Diversification: Exhaustive Induced Pluripotent Stem Cells information about new services, untapped geographies, latest advances, and also investments.

2.Strong Assessment: start to finish examination of stocks, plans, organizations, and amassing capacities of these best players.

3.Business Penetration: Comprehensive information on Induced Pluripotent Stem Cells made accessible the very active players in the global sector.

4.Product Development/Innovation: Comprehensive information about technology, R&D pursuits, together with brand new product launches out of the global Induced Pluripotent Stem Cells market.

5.Market Development: Comprehensive information regarding flourishing emerging markets which the report assesses the market to get Induced Pluripotent Stem Cells worldwide record.

Read Detailed Index of full Research Study at:https://www.marketresearchstore.com/report/global-induced-pluripotent-stem-cells-market-report-2018-269066

The global Induced Pluripotent Stem Cells market research report consists of the opportunities present in the market over the various end user segments. The report involves all the key players Organogenesis Inc., Bone Therapeutics SA, Stemgent, Regeneus Ltd., Axiogenesis, Waisman Biomanufacturing, System Biosciences, CellTherapies P/L, Medipost Co. Ltd., Fate Therapeutics, BrainStorm Cell Therapeutics Inc., Lonza, Reprocell, Ocata Therapeutics of the Induced Pluripotent Stem Cells market and also all the prominent players involved in the global Induced Pluripotent Stem Cells market. The global regional analysis of the Induced Pluripotent Stem Cells market was conducted and is mentioned in the global Induced Pluripotent Stem Cells market research report. The global Induced Pluripotent Stem Cells market research report also elaborates the major dominating regions according to the segments as well as reports the emerging regions in the market. This helps in the proper understanding of the Induced Pluripotent Stem Cells market, its trends, new development taking place in the market, behavior of the supply chain and the technological advancement of the market.

There are 15 Sections to show the global Induced Pluripotent Stem Cells market

Sections 1, Definition, Specifications and Classification of Induced Pluripotent Stem Cells , Applications of Induced Pluripotent Stem Cells , Market Segment by Regions; Section 2, Gathering Cost Structure, Crude Material and Suppliers, Amassing Methodology, Industry Chain Structure; Sections 3, Technical Data and Manufacturing Plants Analysis of Induced Pluripotent Stem Cells , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis; Sections 4, Generally Market Examination, Limit Examination (Association Piece), Sales Examination (Association Bit), deals Esteem Examination (Association Segment); Sections 5 and 6, Regional Market Investigation that incorporates United States, China, Europe, Japan, Korea and Taiwan, Induced Pluripotent Stem Cells segment Market Examination (by Sort); Sections 7 and 8, The Induced Pluripotent Stem Cells Segment Market Analysis (by Application) Major Manufacturers Analysis of Induced Pluripotent Stem Cells ; Sections 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Adult Sources, Fetal Sources, Others Market Trend by Application Hematopoietic stem cell transplantation, Tissue repair damage, Autoimmune diseases, As gene therapy vectors.; Sections 10, Local Advancing Sort Examination, Overall Trade Type Examination, Stock system Examination; Sections 11, The Customers Examination of global Induced Pluripotent Stem Cells; Sections 12, Induced Pluripotent Stem Cells Research Findings and Conclusion, Appendix, system and information source; Sections 13, 14 and 15, Induced Pluripotent Stem Cells deals channel, wholesalers, merchants, traders, Exploration Discoveries and End, appendix and data source.

For more information on this Induced Pluripotent Stem Cells Report, Inquiry Here:https://www.marketresearchstore.com/report/global-induced-pluripotent-stem-cells-market-report-2018-269066#InquiryForBuying

The revenue generated through the sales from all the segments and sub-segments leads us to calculate the Induced Pluripotent Stem Cells market size. To validate the data, top down approach and bottom up approach were carried during the research. All the necessary methodical tools are used to perform a deep study of the global Induced Pluripotent Stem Cells market.

Original post:
Global Induced Pluripotent Stem Cells Market To Witness Huge Gains Over 2020-2026 - Factory Gate

Exosomes act as messengers and decoys to save healthy cells from viral infection – Massive Science

In 2007, scientists developed a method to determine the sexes of Atlantic walruses using only their jaws' size and shape. Researchers have now put that sexing (identification of an organism's sex) method to the test with Pacific walruses.

There was some doubt about whether this technique would work for one, Pacific walruses are significantly larger than their Atlantic counterparts. This size difference shows even in individual body parts, including the mandibles.

Yet, the team, led by Nathan Taylor at the University of Alaska, Fairbanks, persisted in applying the sex identification strategy since, if successful, it would significantly reduce the time and financial commitment needed for researching preserved, unidentified walrus specimens. To distinguish between male and female Pacific walruses, they measured the length and height of the jawbone, the minimum jawbone depth (from about the middle point of the jaw to the back), and jaw thickness.

A female Pacific walrus and a calf

USFWS via Wikimedia

The scientists had to be mindful of whether the jawbones were "not fully fused" (not fully developed, unique to juvenile walruses) or "fused" (fully developed, the sign of a mature walrus). Walruses with partially fused mandibles were likely to yield misleading results.

For example, jaws from male walruses that had not yet fully fused were similar in dimensions to mature females' jaws. To ensure the results were accurate, they could only include fully matured, fused specimens.

After measuring 67 modern specimens (33 of which were male, 24 belonging to females, and ten unknown) and 11 archaeological samples, the researchers concluded that jaw size is indeed a reliable body part to distinguish between male and female walruses. The most significant differences were jaw length and thickness, with females notably smaller in both categories.

A male Pacific walrus

Joel Garlich-Miller, USFWS, via Wikimedia

With the original sexing method now confirmed to work for Pacific walruses, scientists will be better prepared to perform several types of analyses, including measuring stable isotopes, trace elements, and hormones in study animals, with greater confidence and less risk of misidentification.

This is a crucial finding, given the insufficient data on Pacific walrus populations, and will hopefully push conservation efforts for this species forward.

Read more:
Exosomes act as messengers and decoys to save healthy cells from viral infection - Massive Science

Scientists have restored youth to aging eyes in mice – Massive Science

Following the harassment of Christian Cooper in Central Park in May 2020, Black birders created #BlackBirdersWeek to celebrate Black nature enthusiasts and highlight their belonging in outdoor spaces. Since then, dozens of campaigns have emerged to amplify and appreciate Black academics, scientists, and naturalists.

Next up is #BlackInMarineScienceWeek, running from November 29th to December 5th.Led by founder Dr. Tiara Moore and organizers Amani Webber-Schultz, Dr. Camille Gaynus, Carlee Jackson, Al Troutman, Jasmin Graham, Jeanette Davis, Kris Howard, Leslie Townsell, Kaylee Arnold, and Jaida Elcock, this week represents an opportunity for community building and improved representation.

There are few Black folks in ecology and even fewer in marine ecology, says Arnold, a science communicator and disease ecologist. The network that Ive gained through organizing this week is phenomenal. Meeting other Black marine scientists and showing that to the world, especially young Black folks, is a way to say we exist, were here. We have a full day dedicated to young kids, which is unique and exciting.

The organizers hope that the week will help normalize Black folks doing marine research, inspire younger generations, and remind everyone to check their preconceived notions.

"When I say I study sharks people seem concerned about my swimming or my hair, [and] sometimes respond with 'Oh, thats super interesting'... I dont know if that's because it's unusual for people to study sharks or because Im Black and I study sharks, recalls Elcock, an elasmobranch movement ecologist, science communicator, and co-founder of Minorities in Shark Science. Science is for everybody. People say there isn't diversity because [Black] people arent interested... thats clearly not true theres a whole week dedicated [to it]."

Discussion this week will address the fact that exclusion, not lack of interest, led to todays lack of representation. Centuries of segregation and underinvestment in Black neighborhood pools led to, and are perpetuated by, these incorrect and harmful ideas.

My grandparents and my mom said there were just no pools for her to go to... I had a very different experience. Despite people trying to push us out of the water and science, we persevered, and now we get to break down those stereotypes, notes Arnold.

Black in Marine Science Week is here to do just that, showcasing organizers and participants from every imaginable marine science niche, all shaping how society views the oceans and its inhabitants.

There's more Black folks than even we know and are showcasing. I hope that if the media picks up on the number of us as well, and has better representation. Seminar series are extremely white, and now you have a resource of people you can invite instead, emphasizes Arnold, pointing to the necessity of non-Black marine scientists to step up and ensure representation continues beyond this joyous and educational week.

Here is the original post:
Scientists have restored youth to aging eyes in mice - Massive Science

Top Technical Advances of 2020 – The Scientist

COVID-19 diagnostics

A mockup of an at-home test

MAMMOTH BIOSCIENCES

Much of the world became aware of the disease now known as COVID-19 in January, and impressively, a diagnostic PCR test became available the same month. Weve since seen an explosion in potential variations on that assay, including saliva tests, which bypass the need for scarce swabs, and a slew of techniques that could be considerably faster and cheaper than PCR, including breath tests, at-home antigen tests, a diagnostic that combines loop-mediated isothermal amplification (LAMP) and CRISPR, and even an AI model that detects telltale signs of COVID-19 from CT scans.

While diagnostics gave us hard numbers on SARS-CoV-2s devastating sweep, the rapid development of vaccines against it allowed us to imagine the pandemic coming under control. mRNA vaccines from Pfizer and Moderna were among the early leaders of the vaccine race, training the spotlight on a newer technique that had been attempted for other diseases but had not yet made it to the market before 2020. The principle is to deliver a stretch of viral mRNA to recipients cells, which go on to manufacture viral proteins from the transcripts, provoking an immune response.

The year also saw researchers experimenting with other innovative ways of producing vaccines. In one examplewhich, unlike with mRNA vaccines, would avoid the need for cold temperatures during transport and storageresearchers showed that a flu vaccine delivered orally as a thin film induced an immune response in mice.

A colony of spotted wing Drosophila flies entomologist Hannah Burrack maintained at home

COURTESY HANNAH BURRACK

The pandemics effects on science were far-reaching, and necessitated adaptation as many researchers were shut out of their labs in a bid to prevent infection. Among the creative means scientists devised to continue their work was Cut&Tag@home, a protocol for profiling chromosome components that Steven Henikoff of the Fred Hutchinson Cancer Research Center devised in his laundry room.

Induced pluripotent stem cells (iPSCs) have proved a boon to research, but most labs grow the cells in expensive commercial media that require frequent tending to replenish the stock. In a paper at the start of this year, researchers described a DIY recipe for a medium with ingredients that cost a fraction of what commercial alternatives do, and that only needs to be changed every 3.5 days, enabling caretakers to have weekends off.

Neurositys Notion headset, released in 2019, is one of a handful of consumer brain-computer interface devices that scientists are adapting for their EEG research.

STEVE GONG

Collecting data on humans brain activity typically requires researchers to put their subjects into expensive MRI or PET scanners, or to affix wires to their skulls for a traditional EEG setup. But advances in brain-computer interface (BCI) technologymuch of it made with an eye toward the consumer market for devices that could be used for applications such as gaminghold the potential for neuroscientists to gather a wealth of brain activity information as subjects go about their daily activities. The field continued to advance this year with the release of two new BCI headsets, NextMind, which decodes visual attention, and the Neurosity Notion 2, an upgraded iteration of a product that, while designed for coders, can also be used to collect research data.

Read this article:
Top Technical Advances of 2020 - The Scientist

A new psychedelic drug gives psychiatric benefits without causing hallucinations – Massive Science

Following the harassment of Christian Cooper in Central Park in May 2020, Black birders created #BlackBirdersWeek to celebrate Black nature enthusiasts and highlight their belonging in outdoor spaces. Since then, dozens of campaigns have emerged to amplify and appreciate Black academics, scientists, and naturalists.

Next up is #BlackInMarineScienceWeek, running from November 29th to December 5th.Led by founder Dr. Tiara Moore and organizers Amani Webber-Schultz, Dr. Camille Gaynus, Carlee Jackson, Al Troutman, Jasmin Graham, Jeanette Davis, Kris Howard, Leslie Townsell, Kaylee Arnold, and Jaida Elcock, this week represents an opportunity for community building and improved representation.

There are few Black folks in ecology and even fewer in marine ecology, says Arnold, a science communicator and disease ecologist. The network that Ive gained through organizing this week is phenomenal. Meeting other Black marine scientists and showing that to the world, especially young Black folks, is a way to say we exist, were here. We have a full day dedicated to young kids, which is unique and exciting.

The organizers hope that the week will help normalize Black folks doing marine research, inspire younger generations, and remind everyone to check their preconceived notions.

"When I say I study sharks people seem concerned about my swimming or my hair, [and] sometimes respond with 'Oh, thats super interesting'... I dont know if that's because it's unusual for people to study sharks or because Im Black and I study sharks, recalls Elcock, an elasmobranch movement ecologist, science communicator, and co-founder of Minorities in Shark Science. Science is for everybody. People say there isn't diversity because [Black] people arent interested... thats clearly not true theres a whole week dedicated [to it]."

Discussion this week will address the fact that exclusion, not lack of interest, led to todays lack of representation. Centuries of segregation and underinvestment in Black neighborhood pools led to, and are perpetuated by, these incorrect and harmful ideas.

My grandparents and my mom said there were just no pools for her to go to... I had a very different experience. Despite people trying to push us out of the water and science, we persevered, and now we get to break down those stereotypes, notes Arnold.

Black in Marine Science Week is here to do just that, showcasing organizers and participants from every imaginable marine science niche, all shaping how society views the oceans and its inhabitants.

There's more Black folks than even we know and are showcasing. I hope that if the media picks up on the number of us as well, and has better representation. Seminar series are extremely white, and now you have a resource of people you can invite instead, emphasizes Arnold, pointing to the necessity of non-Black marine scientists to step up and ensure representation continues beyond this joyous and educational week.

Read the original here:
A new psychedelic drug gives psychiatric benefits without causing hallucinations - Massive Science

I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic – PRNewswire

Avery Therapeutics is projected to be one of the first companies in the US to seek approval for a clinical trial using iPSC-derived technology for heart failure. The goal of this collaboration is to develop a new off-the-shelf treatment to improve the quality of life of patients suffering from heart failure, a debilitating disease that affects tens of millions of people worldwide.

The iPSCs are manufactured at I Peace's state-of-the-art GMP facility in Kyoto, Japan, under comprehensive validation programs of the facility, equipment, and processes including donor recruiting, screening, blood draw, iPSC generation, storage, and distribution. I Peace has obtained a US-based independent institutional review board (IRB) approval for its process of donor sourcing for commercial-use iPSCs. The facility is designed to be PMDA and USFDA compliant.

As Avery Therapeutics expects to expand the application of its regenerative medicine technology to various types of heart diseases and beyond, iPSCs are the key enabling technology for quality and future scalability. This agreement provides a solid foundation to improve the welfare of those suffering from diseases through advancement of tissue-engineered therapeutics.

"We are thrilled to announce this collaboration with I Peace. It is a big step forward in the development of novel cell-based therapeutics for unmet medical needs. Through this collaboration, I Peace brings deep iPSC development and manufacturing expertise to enable Avery's proprietary MyCardia cell delivery platform technology. Together we hope to positively impact millions of patients worldwide in the near future," Said Jordan Lancaster, PhD, Avery Therapeutics' CEO.

This agreement reflects an innovative collaboration involving multiple locations internationally and marks a significant milestone for both I Peace, Inc. and Avery Therapeutics to pursue one of the first US clinical trials using iPSC technology in the area of heart diseases. Koji Tanabe, PhD, founder and CEO of I Peace stated: "By combining I Peace's proprietary clinical grade iPSC technology and Avery's tissue engineering technology, we can bring the regenerative medicine dream closer to reality. We are very excited by Avery's technology and look forward to continue working together."

About I Peace, Inc

I Peace, Inc. is a global supplier of clinical and research grade iPSCs. It was founded in 2015 in Palo Alto, California, USA by Dr. Tanabe, who earned his doctorate at Kyoto University under Nobel laureate Dr. Shinya Yamanaka. I Peace's mission is to alleviate the suffering of diseased patients and help healthy people maintain a high quality of life by making cell therapy accessible to all. I Peace's state-of-the-art GMP facility and proprietary manufacturing platform enables the fully-automated mass production of discrete iPSCs from multiple donors in a single room. Increasing the available number of clinical-grade iPSC lines allows I Peace customers to take differentiation propensity into account to select the most appropriate iPSC line for their clinical research at significantly reduced cost. I Peace aims to create iPSCs for every individual that become their stem cell for life.

Founder, CEO: Koji Tanabe Since: 2015 Head Quarter: Palo Alto, California Japan subsidiary: I Peace, Ltd. (Kyoto, Japan) Cell Manufacturing Facility: Kyoto, Japan Web: https://www.ipeace.com

About Avery Therapeutics

Avery Therapeutics is a company developing advanced therapies for patients suffering from cardiovascular diseases. Avery's lead candidate is an allogeneic tissue engineered cardiac graft, MyCardia in development for treatment of chronic heart failure. Using Avery's proprietary manufacturing process MyCardia can be manufactured at scale, cryopreserved, and shipped ready to use. Avery is leveraging its proprietary tissue platform to pursue other cardiovascular indications. For more information visit: AveryThera.com. Follow Avery Therapeutics on LinkedInand Twitter. Since: 2016 Headquarter: Tucson, AZ Website: https://www.AveryThera.com

SOURCE I Peace, Inc.

Go here to see the original:
I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic - PRNewswire